Merck (MRK) Asset Writedowns and Impairment (2010 - 2023)

Merck (MRK) has 14 years of Asset Writedowns and Impairment data on file, last reported at $779.0 million in Q4 2023.

• Quarterly Asset Writedowns and Impairment fell 7.15% year-over-year to $779.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.8 billion (up 38.41% YoY) and the FY2025 annual result came in at $55.0 million, up 41.03% from the prior year.
• Asset Writedowns and Impairment retreated to $779.0 million in Q4 2023 per MRK's latest filing, from $839.0 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $1.7 billion in Q4 2020 and bottomed at $15.0 million in Q3 2020.
• The 5-year median for Asset Writedowns and Impairment is $302.0 million (2021), against an average of $505.9 million.
• Peak annual rise in Asset Writedowns and Impairment reached 856.25% in 2020, while the deepest fall reached 97.55% in 2020.
• Tracing MRK's Asset Writedowns and Impairment over 5 years: stood at $176.0 million in 2019, then soared by 856.25% to $1.7 billion in 2020, then slumped by 82.06% to $302.0 million in 2021, then jumped by 177.81% to $839.0 million in 2022, then fell by 7.15% to $779.0 million in 2023.
• Per Business Quant, the three latest MRK Asset Writedowns and Impairment figures stand at $779.0 million (Q4 2023), $839.0 million (Q4 2022), and $887.0 million (Q3 2022).

Peer Comparison